SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* MARDUEL ALIX (Last) (First) (Middle) ONE EMBARACDERO CENTER, SUITE 4050 (Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/14/2004	3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Preferred Stock	(1)	(2)	Common Stock	1,698,274	(3)	I	see Remarks

Explanation of Responses:

1. Immediately

2. Not applicable

3. Each Share is convertible without consideration into one (1) share of Common Stock.

Remarks:

Alix Marduel, Director, is a managing director ("md") of Alta BioPharma Management II, LLC ("ABMII") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABPII")) and a manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBII"). She disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of her proportionate pecuniary interests therein. Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds, including ABPII and AEBII. The respective md and managers of ABPII and AEBII exercise sole voting and investment powers over the shares held by such funds. ABPII beneficially owns 1,632,012 shares of Series C Preferred Stock and AEBII beneficially owns 66,262 shares of Series C Preferred Stock. Jean Deleage, Alix Marduel and Farah Champsi (collectively known as the "principals") are managing directors of ABMII and managers of AEPII. As managing directors and managers, they may be deemed to share voting and investment powers over the shares held by the aforementioned funds. The principals disclaim beneficial ownership of the shares held by ABPII and AEBII except to the extent of their proportion pecuniary interests therein.

	/s/ Fred Kurland, CFO of Corcept Therapeutics Incorporated attorney-in-fact	04/14/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY FOR SECTION 16 REPORTING
The undersigned hereby appoints Joseph K. Belanoff, in his capacity as
Chief Executive Officer of Corcept Therapeutics Incorporated (the "Company"),
Fred Kurland, in his capacity as Chief Financial Officer of the Company, and
either of them with full power of substitution or their respective successors in any
such offices, as the attorney-in-fact of the undersigned to execute and file with the
Securities and Exchange Commission ("SEC") and any other authority required by
the rules and regulations of the SEC or any market or exchange on which shares of
the Company are traded and to submit to the Company, in the place and stead of
the undersigned, SEC Forms 3, 4 and 5 and any successor reporting forms
required by the SEC in connection with purchases and sales of securities of the
Company and any other transactions in securities of the Company reportable on
any such form.  This Power of Attorney shall be effective until revoked by a
written instrument executed by the undersigned and delivered to the Company at
its headquarters to the attention of the Chief Financial Officer.
Dated:  April 8, 2004

/s/ Alix Marduel
Name:  Alix Marduel